alt

48th International Liver Congress (EASL 2013)

April 24-28, 2013, Amsterdam

EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis

The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more:

EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients

European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the EASL International Liver Congress (EASL 2013) in Amsterdam last week. However, clear differences in opinion emerged between patients and doctors regarding who should make decisions about acceptable levels of risk to patients during a symposium on compassionate use organized by the European Liver Patients Association.alt

Read more:

EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients

Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress(EASL 2013) in Amsterdam. People with genotype 3, however, did not respond as well as those with genotype 2.

alt

Read more:

EASL 2013: HCV Protease Inhibitor Simeprevir Pushes Triple Therapy Cure Rate Up to 80%

A second-generation HCV protease inhibitor, simeprevir (formerly TMC435), cured around 80% of previously untreated people with genotype 1 hepatitis C infection when combined with pegylated interferon and ribavirin, Michael Manns of the University of Hannover Medical School reported last week at the EASL International Liver Congress (EASL 2013) in Amsterdam. Overall, 91% of simeprevir-treated patients able to stop all treatment after 24 weeks.

alt

Read more:

EASL 2013: Sofosbuvir + Interferon/Ribavirin Cures 90% of People with Hard-to-Treat HCV Genotypes

Adding the second-generation HCV polymerase inhibitor sofosbuvir (formerly GS-7977) to pegylated interferon plus ribavirin led to a sustained response rate of 89% for treatment-naive patients with HCV genotype 1 in the NEUTRINO study, researchers reported at the EASL International Liver Congress(EASL 2013) last week in Amsterdam. High rates were also seen for the less common genotypes 4, 5 and 6.

alt

Read more: